ProPhase Labs, Inc. Restricted Cash
ProPhase Labs, Inc. (PRPH) had Restricted Cash of $540.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCash · last filed 2024-03-29
- 2023-12-31: Restricted Cash $540.00K.
- 2022-12-31: Restricted Cash $0.00.
- 2021-12-31: Restricted Cash $250.00K.
- 2021-09-30: Restricted Cash $250.00K.
| Period end | Restricted Cash |
|---|---|
| 2023-12-31 | $540.00K 10-K · filed 2024-03-29 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2021-12-31 | $250.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $250.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |